This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

In one embodiment, a hydrogel-enzyme construct for performing high temperature enzymatic reaction on paraoxon, and/or for performing enzymatic reaction on paraoxon following exposure to high temperature, includes a hydrogel having multiple layers of poly(methacrylic acid) (PMAA) and a plurality of dPTE2 enzyme molecules. Individual dPTE2 enzyme molecules are embedded between adjacent PMAA layers and are covalently bonded with respective individual PMAA layers. The hydrogel-enzyme construct is capable of performing enzymatic reaction on the paraoxon when the paraoxon is exposed to the hydrogel-enzyme construct under a temperature condition of up to above 99? C. and below 100? C. or when the paraoxon is exposed to the hydrogel-enzyme construct after the hydrogel-enzyme construct has been heated to a temperature condition of up to 550? C., where the enzymatic reaction on the paraoxon by individual dPTE2 molecules embedded within the hydrogel occurs at a residual activity of between 20% and 100%.

The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the linker includes a first and second functional groups specific for irreversibly inhibiting the first and second fusion protein reactive enzymes. The disclosure further provides a method including (a) contacting a first fusion protein including an affinity reagent and a reactive enzyme with a linker including a functional group specific for irreversibly inhibiting the first fusion protein reactive enzyme thereby coupling the first fusion protein and the linker, and (b) contacting a second fusion protein including an affinity reagent and a reactive enzyme with the linker, the linker including a functional group specific for irreversibly inhibiting the second fusion protein reactive enzyme thereby coupling the second fusion protein and the linker.

Among other things, the present invention is related to devices and methods for improving optical analysis of a thin layer of a sample sandwiched between containing between two plates.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

The present disclosure as disclosed in various embodiments is related to a bioassay for rapid screening and detection of bioactive ligands and screening for potential pharmaceuticals. In various embodiments are disclosed cell-free methods, systems, and kits for detecting bioactive ligands such as endocrine disrupting chemicals or nuclear hormone receptor modulators in a biological or environmental sample or for screening compounds for potential pharmaceutical application such as potential nuclear hormone receptor modulator pharmaceuticals.